Kamada (NASDAQ:KMDA) Releases Earnings Results, Misses Expectations By $0.05 EPS

15 May 2026, 15:46 by Scott Moore · The Cerbat Gem

Kamada (NASDAQ:KMDA – Get Free Report) released its earnings results on Wednesday. The biotechnology company reported $0.07 earnings per share for the quarter, missing analysts’ consensus estimates of $0.12 by ($0.05), FiscalAI reports. Kamada had a net margin of 11.21% and a return on equity of 7.69%. The company had revenue of $45.24 million during the quarter, compared to the consensus estimate of $46.72 million.

Here are the key takeaways from Kamada’s conference call:

Kamada reiterated full-year 2026 guidance for $200 million-$205 million in revenue and $50 million-$53 million in adjusted EBITDA, saying the outlook is based on organic growth only and implies stronger results in the back half of the year.
First-quarter revenue was $42.5 million, up 3% year over year, with growth driven mainly by KEDRAB and the distribution segment. A temporary shipment delay reduced Q1 revenue by about $2.4 million, but the order was already delivered in April.
Management said demand remains strong for key products, especially KEDRAB, which is seeing increased end-user utilization in the U.S. and international markets, and VARIZIG, which is benefiting from product awareness and more chickenpox outbreaks.
The company is expanding its distribution and biosimilars business, with two additional biosimilars expected to launch in Israel by late Q2/early Q3 and a target of roughly 45 products in the Israeli portfolio by year-end. Management also expects biosimilar sales could reach $15 million-$20 million annually over the next four to five years.
Kamada said its newly FDA-approved San Antonio plasma center is cleared to begin commercial normal source plasma sales in the second half of 2026, and both the Houston and San Antonio centers are expected to reach planned capacity toward end-2027/early-2028. The company also noted it remains active on business development and M&A to add products and synergies.

Kamada Stock Down 3.4%

Shares of NASDAQ:KMDA traded down $0.27 during trading on Friday, hitting $7.75. The stock had a trading volume of 50,113 shares, compared to its average volume of 68,294. Kamada has a 12 month low of $6.50 and a 12 month high of $9.35. The company has a market capitalization of $445.70 million, a PE ratio of 22.14, a PEG ratio of 0.61 and a beta of 0.86. The firm’s fifty day moving average is $8.43 and its 200 day moving average is $7.89.

Kamada Dividend Announcement

The company also recently announced an annual dividend, which was paid on Tuesday, April 7th. Stockholders of record on Monday, March 23rd were given a $0.25 dividend. The ex-dividend date of this dividend was Monday, March 23rd. This represents a dividend yield of 305.0%. Kamada’s dividend payout ratio is currently 54.29%.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. NewEdge Advisors LLC raised its position in shares of Kamada by 9.2% in the 4th quarter. NewEdge Advisors LLC now owns 57,538 shares of the biotechnology company’s stock worth $406,000 after acquiring an additional 4,870 shares in the last quarter. XTX Topco Ltd purchased a new stake in shares of Kamada in the 4th quarter worth approximately $103,000. Quadrature Capital Ltd grew its stake in shares of Kamada by 53.5% in the 4th quarter. Quadrature Capital Ltd now owns 21,889 shares of the biotechnology company’s stock worth $155,000 after buying an additional 7,627 shares during the last quarter. Man Group plc grew its stake in shares of Kamada by 19.9% in the 4th quarter. Man Group plc now owns 34,294 shares of the biotechnology company’s stock worth $242,000 after buying an additional 5,684 shares during the last quarter. Finally, SIH Partners LLLP purchased a new stake in shares of Kamada in the 4th quarter worth approximately $134,000. Institutional investors own 20.38% of the company’s stock.

Analyst Ratings Changes

KMDA has been the subject of a number of recent analyst reports. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Kamada in a research report on Thursday, January 22nd. Benchmark reaffirmed a “buy” rating on shares of Kamada in a research report on Thursday, March 12th. Wall Street Zen lowered Kamada from a “strong-buy” rating to a “buy” rating in a research report on Saturday, March 14th. Finally, Stifel Nicolaus set a $11.00 price target on Kamada in a research report on Wednesday, March 11th. Three analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $12.00.

Get Our Latest Stock Report on KMDA

About Kamada

(Get Free Report)

Kamada Ltd. is a biopharmaceutical company headquartered in Israel that specializes in the development, manufacturing and commercialization of plasma‐derived protein therapeutics. The company focuses on treatments for rare and serious diseases, leveraging its proprietary fractionation and purification technologies to produce purified human proteins. Kamada’s product portfolio addresses critical therapeutic areas in immunology, hematology and pulmonology, where alternative treatment options may be limited.